Loading clinical trials...
Loading clinical trials...
Phase II Open Label Multicenter Study of Early REinFusion of Tisagenlecleucel to Promote DUrable B-CEll ApLasia in Pediatric and Young Adult Patients With Relapsed/Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia (REFUEL)
Conditions
Interventions
Tisagenlecleucel
Locations
6
United States
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, United States
Stanford University (Data Collection Only)
Stanford, California, United States
Children's Hospital Colorado (Data Collection Only)
Aurora, Colorado, United States
Johns Hopkins University (Data Collection Only)
Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cincinnati Children's Hospital Medical Center (Data Collection Only)
Cincinnati, Ohio, United States
Start Date
July 12, 2022
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
February 4, 2026
NCT06395103
NCT07523555
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions